[1]
Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci 1991; 81: 233-9.
[2]
Cudic M, Fields GB. Extracellular proteases as targets for drug development. Curr Protein Pept Sci 2009; 10: 297-307.
[3]
Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014; 13: 904-27.
[4]
Sulkava M, Raitoharju E, Levula M, et al. Differentially expressed genes and canonical pathway expression in human atherosclerotic plaques – Tampere vascular study. Sci Rep 2017; 7: 41483.
[5]
Mahdessian H, Perisic Matic L, Lengquist M, et al. Integrative studies implicate matrix metalloproteinase-12 as a culprit gene for large-artery atherosclerotic stroke. J Intern Med 2017; 282(5): 429-44.
[6]
Kousios A, Kouis P, Panayiotou AG. Matrix metalloproteinases and subclinical atherosclerosis in chronic kidney disease: A systematic review. Int J Nephrol 2016; 9498013.
[7]
Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011): An update on behalf of the advisory board of the 3rd and 4th Watching the Risk Symposium 13th and 15th European stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2012; 34(4): 290-6.
[8]
Rysz J, Banach M, Stolarek RA, et al. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 2011; 43: 491-8.
[9]
Ferretti G, Bacchetti T, Banach M, et al. Impact of statin therapy on plasma MMP-3, MMP-9, and TIMP-1 concentrations. Angiology 2017; 68(10): 850-62.
[10]
Hopps E, Caimi G. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci 2015; 19: 2583-9.
[11]
Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother 2015; 16: 1449-61.
[12]
Nikolic D, Nikfar S, Salari P, et al. Lipid and blood pressure meta-analysis collaboration group. Effects of statins on lipid profile in chronic kidney disease patients: A meta-analysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 435-51.
[13]
Su X, Zhang L, Lv J, et al. Effect of statins on kidney disease outcomes: A systematic review and meta-analysis. Am J Kidney Dis 2016; 67: 881-92.
[14]
Konstantinidis I, Nadkarni GN, Yacoub R, et al. Representation of patients with kidney disease in trials of cardiovascular interventions: An updated systematic review. JAMA Intern Med 2016; 176: 121-4.
[15]
Konstantinidis I, Patel S, Camargo M, et al. Representation and reporting of kidney disease in cerebrovascular disease: A systematic review of randomized controlled trials. PLoS One 2017; 12: e0176145.
[16]
McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15: 1912-9.
[17]
Major RW, Cheung CK, Gray LJ, Brunskill NJ. Statins and cardiovascular primary prevention in CKD: A meta-analysis. Clin J Am Soc Nephrol 2015; 10: 732-9.
[18]
Cheng Z, Limbu MH, Wang Z, et al. MMP-2 and 9 in chronic kidney disease. Int J Mol Sci 2017; 18: 776.
